Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion

Neurosurgery

Volumn 41, Issue 6, 1997, Pages 1365-1373

  Sampson, John H ^a,c   Ashley, David M ^a   Archer, Gary E ^a   Fuchs, Herbert E ^a   Dranoff, Glenn ^b   Hale, Laura P ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Animal models; Astrocytomas; Central nervous system neoplasms; Cytokines; Gliomas; VM Dk mice

Indexed keywords

B7 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CARCINOGENICITY; CONTROLLED STUDY; GLIA CELL; GLIOMA; MOUSE; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0030831934     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199712000-00024     Document Type: Article

References (55)

1. Arrick BA, Korc M, Derynck R: Differential regulation of expression of three transforming growth factor β species in human breast cancer cell lines by estradiol. Cancer Res 50:299-303, 1990.
2. Benda P, Lightbody J, Sato G, Levine L, Sweet W: Differentiated rat glial cell strain in tissue culture. Science 161:370-371, 1968.
3. Benda P, Someda K, Messer J, Sweet WH: Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 34:310-323, 1971.
4. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W: Current Protocols in Immunology. New York, Greene and Wiley-Interscience, 1994, pp 3.12.1-3.12.14.
5. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-β1, -β2, and -β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404-1410, 1992.
6. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:187-220, 1972.
7. Danos O, Mulligan RC: Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A 85:6460-6464, 1988.
8. Dasch JR, Waegell WO, Carroll K, Pace DR, Ellingsworth LE: Capture immunoassays specific for TGFβ1 and TGFβ2: Use in pharmacokinetic studies. Ann N Y Acad Sci 593:303-305, 1990.
9. Devajyothi C, Kalvakolanu I, Babcock GT, Vasavada HA, Howe PH, Ransohoff RM: Inhibition of interferon-gamma-induced major histocompatibility complex Class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells: Definition of cis-element. J Biol Chem 268:18794-18800, 1993.
10. Drapoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993.
11. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA Jr: Inhibition of cytokine production by cyclosporin A and transforming growth factor β. J Exp Med 166:571-576, 1987.
12. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci U S A 93:2909-2914, 1996.
13. Fontana A, Hengartner H, de Tribolet N, Weber E: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132:1837-1844, 1984.
14. Fraser H: Astrocytomas in an inbred mouse strain. J Pathol 103: 266-270, 1971.
15. Fraser H: Brain tumours in mice, with particular reference to astrocytoma. Food Chem Toxicol 24:105-111, 1986.
16. Hettmansperger TP, Sheather SJ: Confidence intervals based on interpolated order statistics. Stat Prob Lett 4:75-79, 1986.
17. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33:241-259, 1976.
18. Huber D, Philipp J, Fontana A: Protease inhibitors interfere with transforming growth factor-β-dependent but not the transforming growth factor-β-independent pathway of tumor cell-mediated immunosuppression. J Immunol 148:277-284, 1992.
19. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 87:4207-4211, 1990.
20. Hurford RK Jr, Dranoff G, Mulligan RC, Tepper RI: Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet 10:430-435, 1995.
21. Imperato JP, Paleologos NA, Vick NA: Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28:818-822, 1990.
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
23. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS: Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes. J Immunol 137:3855-3860, 1986.
24. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163:1037-1050, 1986.
25. Kurtzberg J, Hershfield MS: Determinants of deoxyadenosine toxicity in hybrids between human T- and B-lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia. Cancer Res 45:1579-1586, 1985.
26. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:1038-1044, 1995.
27. Meager A: Assays for transforming growth factor β. J Immunol Methods 141:1-14, 1991.
28. Medawar PB: Immunity to homologous grafted skin: Part III -The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58-69, 1948.
29. Morgan KT, Frith CH, Swenberg JA, McGrath JT, Zulch KJ, Crowder DM: A morphologic classification of brain tumors found in several strains of mice. J Natl Cancer Inst 72:151-160, 1984.
30. Pegram CN, Eng LF, Wikstrand CJ, McComb RD, Lee Y-L, Bigner DD: Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species. Neurochem Pathol 3:119-138, 1985.
31. Pilkington GJ, Darling JL, Lantos PL, Thomas DGT: Cell lines (VMDk) derived from a spontaneous murine astrocytoma: Morphological and immunocytochemical characterization. J Neurol Sci 62:115-139, 1983.
32. Pilkington GJ, Lantos PL, Darling JL, Thomas DGT: Three cell lines from a spontaneous murine astrocytoma show variation in astrocytic differentiation. Neurosci Lett 34:315-320, 1982.
33. Prados MD, Gutin PH, Phillips TL, Wara WM, Sneed PK, Larson DA, Lamb SA, Ham B, Malec MK, Wilson CB: Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience. Int J Radiat Oncol Biol Phys 24:593-597, 1992.
34. Ranges GE, Figari IS, Espevik T, Palladino MA Jr: Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 166:991-998, 1987.
35. Renno T, Krakowski M, Piccirillo C, Lin J-Y, Owens T: TNF-α expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis: Regulation by Th1 cytokines. J Immunol 154: 944-953, 1995.
36. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor β on the functions of natural killer cells: Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136:3916-3920, 1986.
37. Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res 51[Suppl]:5074S-5079S, 1991.
38. Roszman TL, Brooks WH: Immunobiology of primary intracranial tumours: Part III - Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumors. Clin Exp Immunol 39:395-402, 1980.
39. Roszman TL, Brooks WH, Markesbery WR, Aziz GJ, Bigner DD: Lymphocyte subpopulations and responsiveness in rats bearing intracranial tumors induced by avian sarcoma virus. J Neurosurg 55:554-559, 1981.
40. Roszman TL, Brooks WH, Markesbery WR, Bigner DD: General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors. Cancer Res 38:74-77, 1978.
41. Rubinstein LJ: Correlation of animal brain tumor models with human neuro-oncology. Natl Cancer Inst Monogr 46:43-49, 1977.
42. Sampson JH, Archer GE, Ashley DM, Fuchs HE, Hale LP, Dranoff G, Bigner DD: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CDS+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93:10399-10404, 1996.
43. Serano RD, Pegram CN, Bigner DD: Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol (Berl) 51:53-64, 1980.
44. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, Glatstein E: National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: Results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30:583-590, 1994.
45. Tanaka K, Gorelik E, Watanabe M, Hozumi N, Jay G: Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex Class I gene. Mol Cell Biol 8:1857-1861, 1988.
46. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matei C, Koutcher J, Gilboa E, Blasberg R: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-γ. Cancer Res 55:1902-1910, 1995.
47. 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A 87:1486-1490, 1990.
48. Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahl LM, Ellingsworth L, Schmidt JA, Hall G, Roberts AB, Sporn MB: Transforming growth factor-β is a potent immunosupressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol 140:3026-3032, 1988.
49. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M: The 9L rat brain tumor: Description and application of an animal model. J Neurol 224:183-192, 1981.
50. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55:3140-3148, 1995.
51. Wong GHW, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW: Inducible expression of H-2 and Ia antigens on brain cells. Nature 310:688-691, 1984.
52. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 6:1633-1636, 1987.
53. Young HR, Sakalas R, Kaplan AM: Inhibition of cell-mediated immunity in patients with brain tumors. Surg Neurol 5:19-23, 1976.
54. Yu JS, Wei MS, Chiocca EA, Martuza RL, Tepper RI: Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 53:3125-3128, 1993.
55. Zuber P, Kuppner MC, de Tribolet N: Transforming growth factor-β2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 18:1623-1626, 1988.